ArticleBrain, behavior, and immunity2026
Complement contributes to hyperactive behavior in the 16p11.2 hemideletion mouse model.
Article in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Disruption of Cell-Type-Specific Molecular Programs of Medium Spiny Neurons in Autism.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
The complement system is a major component of the innate immune system and plays an important role in immune surveillance. Recent research has demonstrated that the complement system also plays pivotal roles in brain development, and dysregulation of complement is involved in neurodegenerative and neuropsychiatric disorders. However, the mechanisms by which the complement system contributes to neurodevelopmental disorders (NDDs) remain poorly understood. In this study, we find that the expression of complement components, including complement C3a receptor (C3aR), is upregulated in the striatum of mice modeling the 16p11.2 hemideletion (16p11.2 del). 16p11.2 del is among the most common copy number variations associated with NDDs including attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and intellectual disability (ID). Pharmacological inhibition of C3aR reduces hyperactivity in 16p11.2 del mice, suggesting that potentiated complement signaling contributes to NDD-relevant behavioral changes. Several cytokines are also upregulated in 16p11.2 del mice striatum, a key neural substrate for locomotor behavior, where we also observe morphological and transcriptional indications of reactive microglia. C3aR inhibition suppresses the elevated expression of interferon-stimulated genes in the 16p11.2 del striatum suggesting that crosstalk between complement and interferon signaling may influence microglial state and hyperactivity in 16p11.2 del mice. Collectively, these data indicate that increased expression of the complement system exacerbates hyperactive behavior and is associated with microglial responses in the striatum of 16p11.2 del mice. Our results suggest that inhibition of the complement system may be an effective strategy to ameliorate NDD symptoms resulting from 16p11.2 hemideletion including those associated with ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.